Ohcanbohtosat - Klesper K

Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective Dahkki Schwander B, Klesper K, Rossol S, Herrmann K, Zoellner YF

Connect to this object online.